<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Haematology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C1C5ABD2-33BD-46CB-886D-987A1BE45436"><gtr:id>C1C5ABD2-33BD-46CB-886D-987A1BE45436</gtr:id><gtr:firstName>Amit</gtr:firstName><gtr:otherNames>Chunilal</gtr:otherNames><gtr:surname>Nathwani</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1C74F08A-DACF-4A6D-8B8C-87B2D60CDB7F"><gtr:id>1C74F08A-DACF-4A6D-8B8C-87B2D60CDB7F</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:otherNames>G</gtr:otherNames><gtr:surname>Tuddenham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0502121"><gtr:id>3589877D-B535-445D-BBEF-E29065843852</gtr:id><gtr:title>AN OPEN LABEL DOSE-ESCALATION STUDY OF A SELF COMPLEMENTARY AAV VECTOR FOR GENE THERAPY OF HAEMOPHILIA B</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502121</gtr:grantReference><gtr:abstractText>In the proposed study we wish to test a new approach called gene therapy for the treatment of patients with haemophilia B. This inherited disorder in which life threatening bleeding occurs without trauma results from an absence or defect of a blood clotting protein called Factor IX (FIX) that arises due to mutations in the FIX gene. The goal of our gene therapy approach, therefore, is to treat the disease by transferring to the patient s liver, a normal copy of the FIX gene so that normal FIX protein can be continuously produced by the patient s own cells. To this end we have developed a novel vector based on adeno-associated virus (scAAV2/8-LP1-FIXco) which is highly efficient at transferring the normal FIX gene to the liver, its natural site of synthesis. Importantly, AAV has the best safety profile among gene transfer vectors of viral origin. In murine and nonhuman primate models we have consistently achieved long-term expression of human FIX at levels that would be sufficient to prevent spontaneous life threatening bleeding in haemophilia B patients following a single injection of scAAV2/8-LP1-FIXco. The vector is simply infused into a peripheral vein, a highly convenient route of administration that dispenses with the need for surgical intervention for efficient transfer of the FIX gene to the liver. Based on these encouraging preclinical results we wish to evaluate this vector system in a small number of adults with severe haemophilia B. Eligible subjects, drawn from the worldwide pool of haemophiliacs, will receive explicit and detailed instructions about the risks and merits of this study prior to obtaining their consent for enrolment. Our primary aim is to establish the safety of peripheral vein administration of scAAV2/8-LP1-hFIXco over three different dosage levels. This study, which will be overseen by an international panel of medical experts, will involve a comprehensive plan of investigations to monitor safety, with particular emphasis on immune response to the virus and normal FIX protein. An additional objective is to determine the dose of vector that is required to achieve stable expression of human FIX at or above 5% of normal levels which would be sufficient to prevent spontaneous bleeding. Success with our approach could significantly impact on a wide variety of life threatening genetic disorders including alpha-1 antitrypsin deficiency, lysosomal storage and urea cycle disorders.</gtr:abstractText><gtr:technicalSummary>Our overriding objective is to develop a safe and effective gene therapy strategy for monogenetic disorders affecting the liver. Using haemophilia B (HB), an X-linked bleeding disorder, as our model system we have developed a novel vector system that is highly efficient at transducing the liver. Based on adeno-associated virus (AAV) which has an excellent safety profile, this vector contains a small liver-restricted human factor IX (hFIX) expression cassette which can be packaged as complementary dimers within individual vector particles. After uncoating these self-complementary (sc) genomes rapidly anneal to form stable, transcriptionally active double-stranded molecules. This unique property results in an almost 3-log improvement in hFIX expression in mice over comparable conventional single stranded AAV vectors. Administration of only 1x1010 scAAV particles resulted in hFIX expression at supraphysiological levels (8IU/ml) and correction of the bleeding diathesis is HB knockout mice without any toxicity. In nonhuman primates a single peripheral vein administration of a low dose of scAAV (1x1012 vector particles[vg]/kg) resulted in mean stable hFIX levels of 20% of normal without any toxicity, even in animals with pre-existing immunity to AAV. This is significantly above hFIX levels required for amelioration of bleeding in HB patients. Based on these encouraging preclinical data, we wish to perform a Phase I/II dose escalation study in adults with severe HB patients who have no evidence of active hepatitis or anti hFIX antibodies. This study is distinct as it involves peripheral vein administration of scAAV8 pseudotyped vectors and will have primary and secondary endpoints of safety and efficacy respectively. Starting with the lowest vector dose, three doses levels (5.0x1011, 1.6x1012 and 5.0x1012vg/kg) will be sequentially assessed in a minimum of two subjects. Enrolment of each subject will proceed only after the previous subject has been observed for at least 42 days. During this time they will undergo a comprehensive array of investigations to assess safety with a particular focus on immune response to hFIX and AAV as well as detection of the vector genomes in semen. A dose will be judged to have exceeded the maximum tolerated dose if Grade III toxicity is observed in two subjects or Grade IV toxicity in one subject, recruited to that dose. A therapeutic vector dose is one that mediates hFIX expression at !Y5% of normal for a minimum of 90 days. Success with this approach will impact on other disorders including lysosomal storage diseases and urea cycle disorders.</gtr:technicalSummary><gtr:fund><gtr:end>2011-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>794190</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Jude Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Surgery</gtr:department><gtr:description>St Jude Children's Research Hospital</gtr:description><gtr:id>D36DA637-820A-4066-83D6-D8ED2F22169B</gtr:id><gtr:impact>Several papers listed in the publication record
Commencement of a Phase I/II clinical trial</gtr:impact><gtr:partnerContribution>Made clinical grade vector for use in the clinical trial for both haemophilia A and B</gtr:partnerContribution><gtr:piContribution>1. Establishment of scale-up of vector production for both FIX and FVIII
2. Development of preclinical data for regulatory approval in UK and USA for both haemophilia A and B
3. Commencement and recruitment of patients to the Phase I/II clinical trial
4. Evaluation of gene transfer efficiency in patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>218538</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Assessing the potential of perinatal gene transfer using congenital factor VII deficiency as a model system)</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>19B5FB36-6963-43E7-B431-AF364A2AB00E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developing gene therapy for bleeding disorders</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>0FC01472-A2A1-4F91-B693-CEC2A4DE6D43</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical Resource/Welcome Trust</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>871A4AB1-F7B9-4E95-8EFC-953EB337B84A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>A new gene therapy strategy is currently being evaluated in clinic with early promising data</gtr:description><gtr:id>4A03CA85-8BDC-44F8-8C58-3B7DDF3EFEBD</gtr:id><gtr:impact>If early results bear out than this will change the way in which patients with haemophilia are treated</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Gene therapy for haemophilia B</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C96C062F-02E5-456C-AC7B-C146EA54FCDC"><gtr:id>C96C062F-02E5-456C-AC7B-C146EA54FCDC</gtr:id><gtr:title>Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fabf686eaf21842f5ea0ebe5c70d8530"><gtr:id>fabf686eaf21842f5ea0ebe5c70d8530</gtr:id><gtr:otherNames>McIntosh JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/378E6146-9E70-4458-A368-95D1B70750A3"><gtr:id>378E6146-9E70-4458-A368-95D1B70750A3</gtr:id><gtr:title>AAV vector biology in primates: finding the missing link?</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41857a295ccc55f38d8e31ffd644b042"><gtr:id>41857a295ccc55f38d8e31ffd644b042</gtr:id><gtr:otherNames>Herzog RW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98242272-4997-4B0F-A3D7-85C09BE12B51"><gtr:id>98242272-4997-4B0F-A3D7-85C09BE12B51</gtr:id><gtr:title>Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/671CCDA5-63A7-4F09-9208-133C9956CAB9"><gtr:id>671CCDA5-63A7-4F09-9208-133C9956CAB9</gtr:id><gtr:title>[Level of nicotinamide coenzymes in the liver and myocardium of rats poisoned with dichlorethane].</gtr:title><gtr:parentPublicationTitle>Biulleten' eksperimental'noi? biologii i meditsiny</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1cbc1b052c6289f69035f137b9f45813"><gtr:id>1cbc1b052c6289f69035f137b9f45813</gtr:id><gtr:otherNames>Natsiuk MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1975-01-01</gtr:date><gtr:issn>0365-9615</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/407B8DF2-6F0E-4C9B-AF24-39015FCC66D1"><gtr:id>407B8DF2-6F0E-4C9B-AF24-39015FCC66D1</gtr:id><gtr:title>Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccf121bcc34f51c5a57fdf14d4642bc0"><gtr:id>ccf121bcc34f51c5a57fdf14d4642bc0</gtr:id><gtr:otherNames>David AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B6EBE84-258D-4309-96CF-62C932A89D63"><gtr:id>7B6EBE84-258D-4309-96CF-62C932A89D63</gtr:id><gtr:title>New and improved AAVenues: current status of hemophilia B gene therapy.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44c4b935756d37ca85a3b8488d63ef26"><gtr:id>44c4b935756d37ca85a3b8488d63ef26</gtr:id><gtr:otherNames>Brimble MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CCAA4D0-C82E-4DEF-BC37-3DCD53734ADF"><gtr:id>4CCAA4D0-C82E-4DEF-BC37-3DCD53734ADF</gtr:id><gtr:title>The case for intrauterine gene therapy.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical obstetrics &amp; gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e4cb902cab54cae8b49c602593c22ca"><gtr:id>9e4cb902cab54cae8b49c602593c22ca</gtr:id><gtr:otherNames>Mattar CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1521-6934</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/571A7A38-31C6-4B94-A84C-98A015848189"><gtr:id>571A7A38-31C6-4B94-A84C-98A015848189</gtr:id><gtr:title>Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/261D164C-7208-449B-8128-2FA9464CF2DB"><gtr:id>261D164C-7208-449B-8128-2FA9464CF2DB</gtr:id><gtr:title>Long-term safety and efficacy of factor IX gene therapy in hemophilia B.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B02DA0D-4200-432F-B876-977100A083CA"><gtr:id>8B02DA0D-4200-432F-B876-977100A083CA</gtr:id><gtr:title>Gene Therapy for Hemophilia.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c4a274803dd01b11758a73553d1e907"><gtr:id>1c4a274803dd01b11758a73553d1e907</gtr:id><gtr:otherNames>Nienhuis AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DADFDA4E-B9DB-4D2E-A650-AC30FD786E3F"><gtr:id>DADFDA4E-B9DB-4D2E-A650-AC30FD786E3F</gtr:id><gtr:title>Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vector.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f788313650c7e804f72bd5761e35e363"><gtr:id>f788313650c7e804f72bd5761e35e363</gtr:id><gtr:otherNames>Piras BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25FFF6C3-4491-4B18-8463-F492F1F29E45"><gtr:id>25FFF6C3-4491-4B18-8463-F492F1F29E45</gtr:id><gtr:title>Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.</gtr:title><gtr:parentPublicationTitle>Expert review of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/010fdc465ec2311544a156919bcf39a8"><gtr:id>010fdc465ec2311544a156919bcf39a8</gtr:id><gtr:otherNames>Raj D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1747-4094</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7749C41D-123C-434F-A937-F35EB9CFEEC5"><gtr:id>7749C41D-123C-434F-A937-F35EB9CFEEC5</gtr:id><gtr:title>Genetic Targeting of the Albumin Locus to Treat Hemophilia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a2a1d62dba372f871437f679c0aec714"><gtr:id>a2a1d62dba372f871437f679c0aec714</gtr:id><gtr:otherNames>Davidoff AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17EE046D-256A-454E-9645-9EE281BE5788"><gtr:id>17EE046D-256A-454E-9645-9EE281BE5788</gtr:id><gtr:title>Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD928989-0BC4-4741-ACE3-2E0B91FD7359"><gtr:id>BD928989-0BC4-4741-ACE3-2E0B91FD7359</gtr:id><gtr:title>Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/072fecabc62f18bb74959d0eb65425b0"><gtr:id>072fecabc62f18bb74959d0eb65425b0</gtr:id><gtr:otherNames>Allay JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F0F9991-2ACC-4518-BEF6-85B1D187870F"><gtr:id>8F0F9991-2ACC-4518-BEF6-85B1D187870F</gtr:id><gtr:title>Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e4cb902cab54cae8b49c602593c22ca"><gtr:id>9e4cb902cab54cae8b49c602593c22ca</gtr:id><gtr:otherNames>Mattar CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8730B90E-DA85-4008-A144-6EBD4314BFFE"><gtr:id>8730B90E-DA85-4008-A144-6EBD4314BFFE</gtr:id><gtr:title>Enhancing transduction of the liver by adeno-associated viral vectors.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C75DF634-B999-4B18-8395-90835EB349B1"><gtr:id>C75DF634-B999-4B18-8395-90835EB349B1</gtr:id><gtr:title>Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502121</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>